Short answer: You cannot run a peptide store on Stripe, Shopify Payments, PayPal, Square or SumUp in 2026. Every one of them prohibits research chemicals and unapproved pharmaceuticals, and their risk systems will find you eventually. What you need is a dedicated high-risk merchant account with an acquiring bank that knowingly underwrites the category, usually at 3.5–5.5% plus a 5–10% rolling reserve, plus a backup rail so a single termination can't take your business offline. If you'd rather skip the reading and just get placed, tell us about your business here and we'll come back with real options within one working day.
I run a research peptide store myself, so everything below is written from the merchant side of the desk as well as the introducer side.
Why peptide merchants get shut down
Peptides are one of the most frustrating categories in online payments precisely because the businesses often look low-risk on paper. Educated customers, low dispute rates, legal products. None of that matters to an aggregator's automated risk model.
Stripe's restricted business list bans pharmaceuticals, pseudo-pharmaceuticals, nutraceuticals and unapproved research chemicals. Shopify Payments runs on Stripe, so it inherits the same rules. PayPal and Square prohibit anything the FDA (or MHRA) hasn't cleared for human use. "For research use only" disclaimers do not override any of this: the platforms classify by product category, not by label.
The detection pattern is depressingly consistent. Automated onboarding approves you. You process for weeks or months. Then a compliance crawler or a manual review picks up compound names (BPC-157, TB-500, GHK-Cu, CJC-1295, semaglutide, tirzepatide) or phrases like "not for human consumption" next to a price, and the account is permanently limited. Whatever balance is in flight gets held for 90 to 180 days. In the worst cases you end up on the MATCH list, which makes every future application harder for up to five years.
2026 has made this worse, not better. Mastercard tightened its BRAM programme specifically around research peptides and nutraceuticals, and a number of processors that were quietly tolerant have either exited the category or re-underwritten their whole book. If you're reading this after a shutdown, you are not alone and it wasn't a mistake on your part. If you're reading it before one, you're ahead of most people.
What a peptide merchant account actually is
A peptide merchant account is a direct relationship with an acquiring bank (or a specialist PSP fronting one) that has explicitly agreed to process research-chemical or GLP-1 transactions. You are underwritten as a business, not auto-approved as an aggregator sub-account. That underwriting is what stops the account disappearing at £50k a month.
There are broadly three flavours in 2026:
- Domestic RUO accounts. Available in the US and, more selectively, the UK and EU. Typically underwritten under MCC 5122 or 5912 as a research-use-only catalogue. Highest authorisation rates (often 95%+), best pricing, strictest site rules.
- Offshore or EU high-risk accounts. More flexible on catalogue and claims, weaker authorisation rates (50–70% is common), higher fees, longer settlement. Useful as a second rail or when a domestic bank won't touch you.
- GLP-1 / clinical accounts. For telehealth clinics, med spas and pharmacies dispensing semaglutide, tirzepatide and similar. Almost always require LegitScript certification and, in the UK, a GPhC-registered pharmacy and prescriber. This is a different regulatory world from research peptides and I'll come back to it.
Because UniqPay is an ISO rather than a single processor, we place merchants across several of these depending on jurisdiction, catalogue and history. That's the whole point of using an introducer: one application, multiple banks, and no incentive to force you into a product that doesn't fit.
What it costs in 2026 (real numbers)
Anyone quoting you a flat percentage before seeing your site and statements is guessing. But here's the honest range we're seeing across placements this year:
- Processing rate: 3.5–5.5% plus a per-transaction fee for compliant domestic accounts. Some brokers publish 6–10% for weak or offshore profiles; if you're being quoted that on a clean UK catalogue, get a second opinion.
- Rolling reserve: 5–10% of volume, held for 90–180 days, released on a rolling basis. On £100k a month that's £10k working capital tied up. Reserves usually come down after three to six months of clean history.
- Monthly and ancillary fees: £25–£100 monthly, £20–£45 per chargeback, occasional setup fees for offshore accounts.
- Approval time: 3–7 working days for a well-prepared application, two weeks to live processing. Missing documents are the number one cause of delay.
Approval rates for properly prepared applications run above 80%. The word "prepared" is doing a lot of work in that sentence.
What underwriters actually check
Every rejection I've seen in this category traces back to one of these:
- Site language. Product pages need scientific, technical descriptions. No weight-loss, anti-ageing, performance or recovery claims, including in customer reviews. Every product carries a research-use disclaimer. Bacteriostatic water is "reconstitution solution". Brand names like Ozempic, Wegovy or Mounjaro on a research site are an instant decline with most RUO banks.
- Policies. Terms, privacy, refund and shipping pages, visible at checkout, matching the descriptor the customer will see on their statement.
- Documents. Certificate of incorporation, ID for directors, three months of bank statements, three to six months of processing statements if you have any, and Certificates of Analysis for each SKU. GLP-1 clinical models add prescriber agreements and LegitScript.
- Chargeback history. Visa's VAMP threshold sits at 1.5% in 2026 and Mastercard's monitoring programmes bite earlier than that. If you're above 1% you need a chargeback plan before you need a new processor.
We review all of this before an application goes anywhere near a bank, because a declined application is far more expensive than a delayed one.
GLP-1 and semaglutide: a separate conversation
If you're selling or prescribing GLP-1 medications rather than research compounds, the rules change completely. In the UK, semaglutide and tirzepatide are prescription-only medicines. Processing for them requires a registered pharmacy, a prescriber, and almost always LegitScript certification, which takes two to four weeks and which card schemes now expect for online prescription sales.
In the US, the FDA removed semaglutide and tirzepatide from the shortage list in May 2025, which ended the legal basis for compounded versions. No acquiring bank will knowingly process for compounded GLP-1s now. Clinics built on that model need to move to approved brands or restructure.
Weight-loss telehealth and clinic accounts are very placeable in 2026, with recurring billing, tokenised card-on-file and dispute alerts built in. But they're placed with different banks under different terms from research peptides, and mixing the two catalogues on one site is one of the fastest ways to lose both.
The backup rails you should have anyway
One card acquirer is not a payment strategy in this category. The merchants who survive 2026 run at least two of:
- A second card acquirer in a different jurisdiction, so a portfolio audit at one bank doesn't stop trading.
- Pay by Bank / open banking (UK and EU). FCA-regulated, no chargebacks, sub-1% pricing, and increasingly accepted by research customers who've hit card declines elsewhere.
- Card-to-crypto settlement. The customer pays by card, you settle in USDC or similar. Useful as a third rail; be careful with the providers, as a lot of the content pushing this is thinly disguised advertising and the fees are rarely as low as advertised.
- ACH / eCheck for US customers, which bypasses card network rules entirely.
We can set up orchestration so these sit behind one checkout with routing rules, but even a manual fallback beats a frozen account with £11k in it.
Common mistakes that get peptide accounts terminated
Opening a fresh Shopify or Stripe account after a ban with the same catalogue (faster ban, and now a pattern on your record). Leaving Shopify Payments enabled "just for a bit" while a real acquirer onboards. Health claims in reviews you forgot to moderate. Selling injection supplies, HCG or nasal sprays alongside research peptides. Using a personal name descriptor that customers don't recognise. Growing past your approved monthly cap without telling the bank. Every one of these is avoidable with ten minutes of planning.
What happens when you get in touch
If you fill in the form below, this is what happens. You'll hear from me, not a call centre. I'll ask for your URL, jurisdiction, monthly volume, and whether you've been terminated before. Within one working day you'll get an honest read on which type of account fits, what the likely rate and reserve look like, and what needs fixing on the site before we apply. If we can't place you, I'll tell you that too and tell you why.
There's no fee to talk, and no fee to apply through UniqPay. We're paid by the acquirer when you're live and processing, so we only get paid when it works.
Get a peptide merchant account quote →
FAQ
Can I sell peptides on Stripe or Shopify Payments in 2026?
No. Both prohibit research chemicals and unapproved pharmaceuticals regardless of disclaimers, and both will terminate the account and hold funds when detected. Disable Shopify Payments before you start selling.
Do I need LegitScript for a peptide merchant account?
Not for a research-use-only catalogue with most domestic banks. Yes for GLP-1 prescription or telehealth models. Requirements vary by acquirer, which is exactly why you want someone who knows which bank wants what.
How long does approval take?
Three to seven working days for a complete application, around two weeks to live processing. Incomplete paperwork is the usual reason it drags.
What if I've already been terminated or MATCH-listed?
Previous termination doesn't disqualify you. MATCH listing narrows the options and raises the cost, but there are banks that will underwrite with the right file. Tell us up front so we don't waste your time.
Can UK peptide businesses get a card merchant account?
Yes, but only through specialist high-risk acquirers who underwrite research-chemical catalogues, and only if the site is claim-free and compliant. Stripe, PayPal, SumUp and Square all ban the category.